Stay updated with breaking news from Phasei Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
“It’s a proud moment to see CF33-hNIS-antiPDL1 (CHECKvacc) continue its progression and have this Phase I trial underway with patients at...
Poster presentation by Pr. Christophe Le Tourneau featuring first OS and PFS data from phase I expansion study of NBTXR3 as a single agent activated by radiotherapy in tough-to-treat HNSCC populationOral presentation by Dr. Tanguy Y. Seiwert with comprehensive review of local and systemic potential effects of NBTXR3...
Poster presentation by Pr. Christophe Le Tourneau featuring first OS and PFS data from phase I expansion study of NBTXR3 as a single agent activated by radiotherapy in tough-to-treat HNSCC population
Imugene collaborator wins FDA Investigational New Drug approval to initiate CHECKvacc phase one trial Imugene managing director and chief executive officer Leslie Chong called the approval a “major milestone” for the company as it prepares to commence a phase one trial into metastatic, triple-negative breast cancer with its CHECKvacc drug candidate. Imugene is a step closer to trialling its oncolytic virotherapy candidate in a phase one study on patients with triple-negative breast cancer. Imugene Limited’s (ASX:IMU) (OTCMKTS:IUGNF) has achieved a major milestone with US col...
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into responders Objective response was observed in 60% of anti-PD-1 naïve patients and 50% of prior non-responders Data suggest abscopal effect in some patients (i.e., reduction in non-injected non-irradiated lesions) To date, the overall adverse event profil...